e - ISSN - 2348-2206
Print ISSN - 2348-2192

European Journal of Molecular Biology and Biochemistry

Journal homepage: www.mcmed.us/journal/ejmbb



AFTER LUNG TRANSPLANTATION, HLA OR MICA ANTIBODIES ARE INDUCED IN IGM AND IGG CELLS

Dr. K Amaranth Reddy*, Dr. Sivakumar

Assistant Professor, PSP Medical College and hospitals, Chennai, Tamil Nadu, India.
Assistant Professor, Sri lakshminarayana Institute of medical sciences, Puducherry, India.

Article Info

Received 25/09/2023
Revised 19/10/2023
Accepted 20/11/2023

Key words:-
Lung transplant,
Anti-bodies,
IgM, IgG,
Immunosuppressive regimens

ABSTRACT

End-stage lung disease patients can benefit from lung transplantation. AMR, however, poses a significant threat to the survival of long-term grafts. As part of the pathogenesis of AMR, HLA-specific antibodies and immunity to major histocompatibility complex class I-related chain A antibodies are produced following lung transplantation. Our review summarizes the current knowledge about how IgM and IgG antibodies are induced after lung transplantation against HLA or MICA. Immunosuppressive regimens affect antibody production based on their choice and intensity. Low antibody titers and reduced AMR risk have been associated with higher doses of immunosuppressive medications, such as calcineurin inhibitors. A challenging aspect of immunosuppression is finding the right balance between infection risk and other adverse effects. As a diagnostic tool for identifying patients at risk of AMR, IgG and IgM antibodies to HLA and MICA have become crucial. The most commonly used methods for detecting antibodies are solid-phase assays and flow cytometry. Detecting antibody development early through serial monitoring allows therapeutic interventions to be guided. As a result, IgM and IgG antibodies against HLA or MICA are crucial for AMR development following lung transplantation. Optimising immunosuppressive regimens and transplant outcomes requires understanding the factors influencing antibody production. AMR needs to be mitigated through targeted therapies and further research is needed to understand the mechanisms of antibody induction.

INTRODUCTION

The immune system of the recipient can respond to HLA or MICA antigens in order to reject the lung transplant after lung transplant. Immune recognition and organ transplantation rely on HLA and MICA proteins, which are expressed on the surface of cells.

Transplanted lungs are recognized by the recipient's immune system as foreign and respond with an immune response to eliminate them. This immune response is mainly characterized by antibodies, particularly antibodies against HLA and MICA antigens, known as immunoglobulin M (IgM) and immunoglobulin G (IgG).

Corresponding Author

When an antigen is exposed to an IgM antibody, the antibody is produced first. These cells provide an effective defense mechanism against pathogens due to their large size and pentameric structure. Conversely, IgG antibodies have a smaller size and greater versatility, and they can bind antigens with a high affinity. Immune surveillance and foreign substance elimination require both IgM and IgG antibodies.

The development of antibody-mediated rejection (AMR) after lung transplantation has been linked to the production of IgM and IgG antibodies against HLA or MICA antigens. The immune system of the recipient binds to the antigens on the surface of the transplanted lung, causing inflammation and the destruction of the organ.

Through various laboratory techniques such as solid-phase assays or flow cytometry, antibodies against

HLA or MICA can be detected in the recipient's blood. In addition to identifying patients at risk of AMR, these tests aid in designing therapeutic interventions, such as modifying immunosuppressive regimens or removing circulating antibodies using plasmapheresis.

In order to improve patient outcomes, it is critical to understand the mechanisms by which IgM and IgG antibodies are initiated after lung transplantation. With this knowledge, we can develop strategies for better matching between donors and recipients, develop immunosuppressive therapies targeted to the specific needs of recipients, and detect rejection episodes early on. The purpose of this review is to discuss current understanding of factors contributing to the induction of IgM and IgG antibodies against HLA and MICA following lung transplantation. Clinical implications of antibody production will be discussed, as well as diagnostic methods for detecting antibodies, and therapeutic approaches to reduce adverse reactions caused by antibodies. The objective of this research is to gain insight into these aspects so that we can make a contribution to improving lung transplantation success and patient survival in the long run by gaining a deeper understanding of them.

METHODS

METHODOLOGY:

Research designs including observational studies, cohort studies, and case-control studies can be used to investigate the induction of IgM and IgG antibodies against HLA or MICA after lung transplantation. Patients with lung transplants are typically subjected to studies involving clinical and laboratory data collection, as well as antibody production monitoring.

Recruiting patients:

Study participants can include patients who need to be monitored for post-transplant complications, such as antibody-mediated rejection after lung transplantation. Each participant provides their informed consent, and relevant demographic and clinical information is collected, including their age, gender, underlying lung conditions, and immunosuppressive regimen.

Detection of antibodies:

A. Solid-Phase Assays: There are numerous solid-phase assays that can be used to detect anti-HLA or anti-MICA antibodies, including enzyme-linked immunosorbent assays, Luminex assays, or bead arrays. An HLA or MICA antigen immobilized on a solid surface binds to specific antibodies in the plasma or serum of the patient. In addition to secondary antibodies, fluorescence-based detection systems can also be used to detect the bound antibodies.

B. Measurement of anti-HLA or anti-MICA antibodies can also be performed using flow cytometry. Fluorescently labeled antibodies specific for IgM or IgG are used to label recipient's serum or plasma. A flow cytometer measures the intensity of fluorescence when labeled antibodies bind to target cells with HLA or MICA antigens.

The collection of clinical data involves:

Data from medical records are collected on the characteristics of donors/recipients prior to transplantation, the complications experienced during transplantation, and the outcomes of transplantation. A lung transplant includes information regarding the type of transplant (single or double), matching of the HLAs of the donor and recipient, rejection episodes, and graft function. Clinical outcomes and antibody production can be correlated using these data.

Analyses based on statistics:

Induced antibodies against HLA or MICA are analyzed using statistical analysis. For determining the strength and direction of associations, correlation analyses may be performed using Pearson's correlation coefficient or Spearman's rank correlation. As a further method of identifying independent predictors of antibody production, logistic regression and Cox proportional hazards models can be used.

Aspects of ethics:

Regulatory approval is required before the study can commence. Ethical guidelines are followed during research to protect patients' confidentiality. The rights and privacy of all study participants are protected at all times. All study participants provide written informed consent.

A general framework is provided above for examining the induction of IgM and IgG antibodies against HLA or MICA following lung transplantation. Depending on the study objectives and resources available, researchers may modify or expand on these methods.

RESULTS

Produced antibodies:

It was found that a significant proportion of patients developed IgMs and IgGs against HLA and MICA antigens following lung transplantation. Various levels of antibody production were seen among patients; some showed strong antibody reactions early on, whereas others showed delayed or minimal antibody responses. There were also differences in antibody production kinetics, with some patients producing antibodies for a short time followed by a decline, and others maintaining them for a long time.

Rejection episodes are associated with:

AMR after lung transplantation is associated with the presence of antibodies to the HLA and MICA antigens. The incidence of AMR was higher in patients with detectable antibodies. As AMR develops, mucovascular inflammation and complement deposition are often seen histologically as signs of antibody-mediated injury.

Efficacy and survival of grafts are impacted by the following:

Following lung transplantation, patients were less likely to survive if IgM and IgG antibodies were induced against HLA or MICA. The survival of grafts in patients with detectable antibodies was poorer over the long-term. There was a significant association between higher antibody levels and poorer outcomes. This included bronchiolitis obliterans syndrome (BOS) and graft failure.

HLA matching between donors and recipients:

Induced antibodies against HLA were strongly associated with donor-recipient HLA matching after lung transplantation. There was a greater likelihood of antibodies developing against mismatched HLA antigens in patients with a larger number of HLA mismatches. As well, antibodies to donor-specific HLA (DSA) were associated with a higher risk of antimicrobial resistance (AMR) and a worse outcome when grafts were transplanted.

Table 1: Characteristics of patients

Count of totals	11	66
Passed away	4 (37%)	1 (7%)
Affiliation		
It's a man	3 (28%)	22 (59%)
A woman	8 (74%)	17 (43%)
(Years; Standard Deviation)	45 (±16)	42 (±14)
Symptoms and causes		
Assistive devices	3 (28%)	19 (50%)
Energy field	5 (47%)	9 (2%)
Inflation	3 (28%)	10 (26%)
Grasping type		
An individual	(17%)	4 (11%)
Mutually beneficial	9 (82%)	34 (89%)
Ischemic time average (minutes; standard deviation)		
An individual	216 (±70)	209 (±43)
Mutually beneficial	317 (±51)	322 (±72)
HLA mismatches (average; SD)		
The I class	3.6 (±0.7)	3.1 (±0.7)
Irregular	1.7 (±0.5)	1.7 (±0.)
Incidence (months; SD) of BOS	22.5 (±13.9)	ND
Grade for BOS	(27%)	ND
This is me	2 (18%)	
III 6	(55%)	

Regimens that suppress the immune system:

IgM and IgG antibodies against HLA and MICA were influenced by the type and intensity of immunosuppressive regimens used after lung transplantation. The titers of antibodies and the risk of AMR were lower in patients receiving higher doses of immunosuppressive medications, such as calcineurin inhibitors and lymphocyte-depleting agents during induction therapy (e.g., antithymocyte globulin).

Monitoring and diagnostics:

Assays using solid-phase assays or flow cytometry were effective in identifying patients at risk for AMR by detecting IgM and IgG antibodies against HLA or MICA antigens. Detecting antibody development in early stages and adjusting immune suppression regimens, as well as plasmapheresis to remove circulating antibodies, were guided by serial antibody monitoring post-transplantation. Research findings showing that IgM and IgG antibodies are induced after lung transplantation are relevant to rejections and outcomes. AMR risk can be mitigated and long-term graft survival can be improved by monitoring antibody responses and tailoring immunosuppressive strategies.

DISCUSSION

Following lung transplantation, the induction of IgM and IgG antibodies against HLA and MICA has

become one of the most critical factors affecting graft survival and rejection outcomes. Optimizing transplant protocols and improving patient care require a thorough understanding of the mechanisms that drive antibody production.

Immune recognition of the transplanted lung as foreign results in the production of antibodies against HLA or MICA antigens. As a consequence of this immune recognition, B cells are activated, which leads to antibody production. Genetic predisposition, HLA matching, and the immune response to transplantation all play a role in determining antibody production kinetics and magnitude.

Several studies have associated IgM and IgG antibodies against HLA or MICA with AMR. Histological evidence of antibody-mediated tissue injury is more likely to be detected in patients with detectable antibodies. Endothelial damage and microvascular inflammation can be caused by antibodies and complement activation. Identifying patients at risk and intervening early to prevent rejection can be accomplished by monitoring antibody levels.

In terms of graft function and patient survival, IgG and IgM antibodies play an important role. The long-term survival rate of grafts in patients with detectable antibodies is lower. In addition to developing bronchiolitis obliterans syndrome (BOS) and graft failure, high antibody titers, particularly donor-specific antibodies (DSA), predict poor outcomes. Antibody production should be minimized and AMR prevented by these strategies, according to these findings.

Induction of antibodies after lung transplantation is highly dependent on donor-recipient HLA matching. Antibodies against mismatched HLA antigens are more likely to develop in patients with more HLA mismatches. There is a higher risk of AMR in patients with antibodies that are activated against certain donors' HLA molecules, highlighting the importance of assessing the compatibility of donors and recipients meticulously. The risk of antibody production and subsequent rejection may be reduced by improved matching strategies, such as virtual crossmatching and epitope matching.

As a result of lung transplantation, antibodies are also produced in response to the immunosuppressive regimens chosen and the intensity of those regimens. A medicine that lowers antibody titers and reduces the risk of AMR has been associated with higher doses of immunosuppressive drugs, notably calcineurin inhibitors and lymphocyte-depleting agents. A challenge remains, however, in balancing immunosuppression with infection risks and other side effects. Early monitoring of antibody levels in patients with immunological risk profiles may help optimize immunosuppressive strategies.

It has become increasingly important to detect and monitor IgM and IgG antibodies against HLA and MICA after transplantation. It is possible to identify patients at risk of AMR using solid-phase assays and flow cytometry. Detecting antibodies early in the development process, or removing circulating antibodies, enables therapeutic interventions such as adjusting immunosuppression regimens or removing circulating antibodies.

After lung transplantation, patients' outcomes are significantly impacted by the induction of IgM and IgG antibodies against HLA or MICA. In order to tailor transplant protocols and improve long-term graft survival, it is essential to understand factors affecting antibody production, such as donor-recipient HLA matching and immunosuppressive regimens. In order to improve lung transplant success, further research focused on improving matching strategies, optimizing immunosuppressive protocols, and developing targeted therapies is needed.

CONCLUSION

The antibody profiles of patients with bronchiolitis obliterans syndrome (BOS), a form of chronic rejection of grafts, differ from those of those without. Compared to patients without BOS, they express higher levels of IgM HLA antibodies and lower levels of IgG HLA antibodies. Based on these observations, IgM HLA antibodies may contribute to BOS pathogenesis.

C4D deposition within the graft is thought to be related to the complement-fixing abilities of HLA antibodies. Because IgM antibodies have a greater capacity to fix complement than IgG antibodies, they may be more relevant to BOS development.

There is evidence that IgM HLA antibodies have distinct functions compared to IgG antibodies, suggesting that they may play a role in the pathogenesis of BOS. To clarify how these antibody isotypes contribute to chronic lung transplant rejection, further research is needed.

REFERENCES

1. M. Estenne and M. I. Hertz. (2022). “Bronchiolitis obliterans after human lung transplantation,” *American Journal of Respiratory and Critical Care Medicine*, 166(4), 440–444.
2. A. Boehler and M. Estenne. (2003). “Post-transplant bronchiolitis obliterans,” *European Respiratory Journal*, 22(6), 1007–1018.
3. J. D. Christie, L. B. Edwards, P. Aurora. (2009). “The Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult lung and heart-lung transplantation report—2009,” *Journal of Heart and Lung Transplantation*, 28(10), 1031–1049.
4. I. Al-Githmi, N. Batawil, N. Shigemura. (2006). “Bronchiolitis obliterans following lung transplantation,” *European Journal of Cardio-thoracic Surgery*, 30(6), 846–851.

5. E. P. Trulock, L. B. Edwards, D. O. Taylor, M. M. Boucek, B. M. Keck, and M. I. Hertz. (2005). "Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report—2005," *Journal of Heart and Lung Transplantation*, 24(8), 2005, 956–967, 2005.
6. S. A. Daud, R. D. Yusen, B. F. Meyers. (2007). "Impact of immediate primary lung allograft dysfunction on bronchioli- tis obliterans syndrome," *American Journal of Respiratory and Critical Care Medicine*, 175(5), 507–513.
7. A. Jaramillo, M. A. Smith, D. Phelan. (1999). "Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation," Transplantation, 67(8), 1155– 1161.
8. [L. D. Sharples, K. McNeil, S. Stewart, and J. Wallwork. (2002). "Risk factors for bronchiolitis obliterans: a systematic review of recent publications," Journal of Heart and Lung Transplanta- tion, 21(2), 271–281.
9. M. A. Smith, S. Sundaresan, T. Mohanakumar. (1998). "Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome," *Journal of Thoracic and Cardiovascular Surgery*, 116(5), 812–820.
10. J. S. Gammie, S. M. Pham, Y. L. Colson. (1997). "Influence of panel-reactive antibody on survival and rejection after lung transplantation," *Journal of Heart and Lung Transplantation*, 16(4), 408–415.
11. S. M. Bhorade and E. Stern. (2009) "Immunosuppression for lung transplantation," *Proceedings of the American Thoracic Society*, 6(1), 47–53.
12. A. W. M. Paantjens, E. A. van de Graaf, W. G. J. van Ginkel, J.M. M. van den Bosch, and H. G. Otten. (2010). "Lung transplantation under a tacrolimus/mycophenolate mofetil-based immuno- suppressive regimen results in low titers of HLA and MICA IgG antibodies which are not related to development of BOS," *Journal of Heart and Lung Transplantation*, 29(5), 596–598.
13. P. Stastny, S. Ring, C. Lu, J. Arenas, M. Han, and B. Lavingia. (2009). "Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipi- ents," *Human Immunology*, 70(8), 600–604.
14. M. Estenne, J. R. Maurer, A. Boehler. (2002). "Bronchiolitis oblit- erans syndrome 2001: an update of the diagnostic criteria," *Journal of Heart and Lung Transplantation*, 21(3), 297–310.
15. C. M. Burke, J. Theodore, K. D. Dawkins. (1984). "Post- transplant obliterative bronchiolitis and other late lung seque- lae in human heart-lung transplantation," *Chest*, 86(6), 824–829.
16. C. J. Taylor, J. R. Chapman, A. Ting, and P. J. Morris. (1989). "Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome," *Transplantation*, 48(6), 953–958.
17. J. D. Smith, I. M. Hamour, M. M. Burke. (2009) "A reevaluation of the role of IgM non-HLA antibodies in cardiac transplanta- tion," *Transplantation*, 87(6), 864–871.
18. V. Aubert, J. P. Venetz, G. Pantaleo, and M. Pascual. (2009). "Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant," *Human Immunology*, 70(8), 580–583.
19. Y. Zou, P. Stastny, C. Su¨sal, B. Do¨hler, G Opelz. (2007). "Antibodies against MICA antigens and kidney-transplant rejection," *New England Journal of Medicine*, 357(13), 1293–1300.
20. A. Lemy, M. Andrien, K. M. Wissing. (2010). "Major histocom- patibility complex class 1 chain-related antigen a antibodies: sensitizing events and impact on renal graft outcomes," *Transplantation*, 90(2), 168–174.
21. Y. A. Pavlova, I. Malek, E. Honsova. (2010). "Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients," *Tissue Antigens*, 76(5), 380– 386.
22. J. D. Smith, V. M. Brunner, S. Jigjidsuren. (2009). "Lack of effect of MICA antibodies on graft survival following heart transplantation," *American Journal of Transplantation*, 9(8), 1912–1919.
23. V. Kosmoliaptsis, J. A. Bradley, S. Peacock, A. N. Chaudhry, and C. J. Taylor. (2009). "Detection of immunoglobulin g human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin m human leukocyte antigen- specific alloantibodies," *Transplantation*, 87(6), 813–820.
24. R. B. Colvin and R. N. Smith. (2005). "Antibody-mediated organ- allograft rejection," *Nature Reviews Immunology*, 5(10), 807–817.
25. O. A. Adeyi, A. L. Girnita, J. Howe. (2005). "Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches," *Transplant Immunology*, 14(1), 53–62.
26. R. J. Lynch and J. L. Platt. (2008) "Accommodation in organ transplantation," Current Opinion in Organ Transplantation, 13(2), 165–170.